Werner Syndrome and Diabetes: Opportunities for Precision Medicine.
Werner Syndrome and Diabetes: Opportunities for Precision Medicine. Diabetes Care. 2024 May 01; 47(5):785-786.
PMID: 38640412
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes.
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes. Diabetes Care. 2024 Mar 01; 47(3):393-400.
PMID: 38151474
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country.
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country. Popul Med. 2024 Mar; 6.
PMID: 38681897
A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life.
A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life. Diabetologia. 2024 May; 67(5):940-951.
PMID: 38366195
Noninsulinoma Pancreatogenous Hypoglycemia Syndrome in a Patient With 1p36 Deletion Syndrome.
Noninsulinoma Pancreatogenous Hypoglycemia Syndrome in a Patient With 1p36 Deletion Syndrome. JCEM Case Rep. 2024 Feb; 2(2):luae003.
PMID: 38304011
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes.
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes. Diabetes Care. 2023 Dec 27.
PMID: 38151474
Stress and human health in diabetes: A report from the 19th Chicago Biomedical Consortium symposium.
Stress and human health in diabetes: A report from the 19th Chicago Biomedical Consortium symposium. J Clin Transl Sci. 2023; 7(1):e263.
PMID: 38229904
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 Oct; 29(10):2438-2457.
PMID: 37794253
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.
PMID: 37068291
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY).
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
PMID: 36637968